Spironolactone Attenuates Experimental Uremic Cardiomyopathy by Antagonizing Marinobufagenin

Spironolactone has been noted to attenuate cardiac fibrosis. We have observed that the cardiotonic steroid marinobufagenin plays an important role in the diastolic dysfunction and cardiac fibrosis seen with experimental renal failure. We performed the following studies to determine whether and how s...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tian, Jiang, Shidyak, Amjad, Periyasamy, Sankaridrug M., Haller, Steven, Taleb, Mohamed, El-Okdi, Nasser, Elkareh, Jihad, Gupta, Shalini, Gohara, Sabry, Fedorova, Olga V., Cooper, Christopher J., Xie, Zijian, Malhotra, Deepak, Bagrov, Alexei Y., Shapiro, Joseph I.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2783263/
https://ncbi.nlm.nih.gov/pubmed/19884563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/HYPERTENSIONAHA.109.140038
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky